<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37744355</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Urine SERPINC1/ORM1 as biomarkers for early detection of lupus nephritis in MRL-lpr mice.</ArticleTitle><Pagination><StartPage>1148574</StartPage><MedlinePgn>1148574</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1148574</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1148574</ELocationID><Abstract><AbstractText Label="BACKGROUND">To evaluate the usefulness of urine SERPINC1 and ORM1 as biomarkers for early detection of lupus nephritis (LN).</AbstractText><AbstractText Label="METHODS">Using proteomics, we screened for potential urine biomarkers that differentiate LN from systemic lupus erythematosus (SLE) patients without nephritis. In addition, urine levels of target biomarkers were measured by ELISA in 13- and 23-week-old MRL-lpr (murine model for LN) and MRL/MpJ mice. Histological analysis was also performed on the kidneys of 23-week-old mice.</AbstractText><AbstractText Label="RESULTS">Urine SERPINC1 and ORM1 were elevated in SLE patients with newly diagnosed LN compared with SLE patients without LN (SERPINC1, AUC=.892, P&lt;.001; ORM1, AUC=.886, P&lt;.001). Levels of urine SERPINC1 and ORM1 were also significantly higher in MRL-lpr mice than in MRL/MpJ mice at 13 and 23 weeks (SERPINC1: p&lt;.01 and p&lt;.001 at 13 and 23 weeks, respectively; ORM1: p&lt;.01 at 13 and 23 weeks). In contrast, a significant difference in urine albumin between the two groups was only observed at 23 weeks (p&lt;.001) not at 13 weeks (p=.83). Regarding the kidney pathology of MPL-lpr mice, urine ORM1 and urine albumin, but not urine SERPINC1, were positively correlated with the activity index (ORM1, rho =.879, p&lt;.001; albumin, rho =.807, p=.003) and chronicity index (ORM1, rho =.947, p&lt;.001; albumin, rho =.869, p&lt;.001).</AbstractText><AbstractText Label="CONCLUSION">We propose that urine SERPINC1 and ORM1 are novel biomarkers for early LN.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Kim, Lee, Kim, Kim, Jeong, Yu, Hong, Lee, Yoo and Kim.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Young-Eun</ForeName><Initials>YE</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eun-Ju</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kyunggon</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Convergence Medicine Research Center, Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Do Hoon</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Mi Ryeong</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Jiyoung</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Convergence Medicine Research Center, Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Seokchan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chang-Keun</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yong-Gil</ForeName><Initials>YG</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Convergence Medicine Research Center, Asan Institute for Life Science, Asan Medical Center, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000418">Albumins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C542513">SERPINC1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>9000-94-6</RegistryNumber><NameOfSubstance UI="D000990">Antithrombin III</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019463" MajorTopicYN="N">Mice, Inbred MRL lpr</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000418" MajorTopicYN="N">Albumins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000990" MajorTopicYN="N">Antithrombin III</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">alpha-1-acid glycoprotein (ORM1)</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">interleukins</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">proteomics</Keyword><Keyword MajorTopicYN="N">serpin peptidase inhibitor clade C (antithrombin) member 1 (SERPINC1)</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>26</Day><Hour>13</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37744355</ArticleId><ArticleId IdType="pmc">PMC10515280</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1148574</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers (2020) 6(1):7. doi:&#xa0;10.1038/s41572-019-0141-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Lee G, Liu X, Pascoe EM, Badve SV, Boudville NC, et al. . Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. Kidney Int (2016) 89(6):1337&#x2013;45. doi:&#xa0;10.1016/j.kint.2016.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2016.02.014</ArticleId><ArticleId IdType="pubmed">27165824</ArticleId></ArticleIdList></Reference><Reference><Citation>Costenbader KH, Desai A, Alarcon GS, Hiraki LT, Shaykevich T, Brookhart MA, et al. . Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum (2011) 63(6):1681&#x2013;8. doi:&#xa0;10.1002/art.30293</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30293</ArticleId><ArticleId IdType="pmc">PMC3106117</ArticleId><ArticleId IdType="pubmed">21445962</ArticleId></ArticleIdList></Reference><Reference><Citation>Sexton DJ, Reule S, Solid C, Chen SC, Collins AJ, Foley RN. Esrd from lupus nephritis in the United States, 1995-2010. Clin J Am Soc Nephrol (2015) 10(2):251&#x2013;9. doi:&#xa0;10.2215/CJN.02350314</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.02350314</ArticleId><ArticleId IdType="pmc">PMC4317731</ArticleId><ArticleId IdType="pubmed">25534208</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau FA, D'Cruz D, Vianna J, Hughes GR. Lupus nephritis: the significance of serological tests at the time of biopsy. Clin Exp Rheumatol (1991) 9(4):345&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1934681</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Zhang X. Biomarkers for lupus nephritis: the quest continues. Clin J Am Soc Nephrol (2009) 4(11):1858&#x2013;65. doi:&#xa0;10.2215/CJN.03530509</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.03530509</ArticleId><ArticleId IdType="pubmed">19729426</ArticleId></ArticleIdList></Reference><Reference><Citation>Simard-Meilleur MC, Troyanov S, Roy L, Dalaire E, Brachemi S. Risk factors and timing of native kidney biopsy complications. Nephron Extra (2014) 4(1):42&#x2013;9. doi:&#xa0;10.1159/000360087</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000360087</ArticleId><ArticleId IdType="pmc">PMC4000304</ArticleId><ArticleId IdType="pubmed">24803920</ArticleId></ArticleIdList></Reference><Reference><Citation>Malvar A, Pirruccio P, Alberton V, Lococo B, Recalde C, Fazini B, et al. . Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant (2017) 32(8):1338&#x2013;44. doi:&#xa0;10.1093/ndt/gfv296</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfv296</ArticleId><ArticleId IdType="pmc">PMC5837387</ArticleId><ArticleId IdType="pubmed">26250434</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon OC, Lee EJ, Yeom J, Hong S, Lee CK, Yoo B, et al. . Discovery of urine biomarkers for lupus nephritis via quantitative and comparative proteome analysis. Clin Transl Med (2021) 11(11):e638. doi:&#xa0;10.1002/ctm2.638</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.638</ArticleId><ArticleId IdType="pmc">PMC8582290</ArticleId><ArticleId IdType="pubmed">34841703</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy JH, Sniecinski RM, Welsby IJ, Levi M. Antithrombin: anti-inflammatory properties and clinical applications. Thromb Haemost (2016) 115(4):712&#x2013;28. doi:&#xa0;10.1160/TH15-08-0687</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH15-08-0687</ArticleId><ArticleId IdType="pubmed">26676884</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Z, Wang F, Liang M. Serpinc1/antithrombin iii in kidney-related diseases. Clin Sci (Lond) (2017) 131(9):823&#x2013;31. doi:&#xa0;10.1042/CS20160669</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CS20160669</ArticleId><ArticleId IdType="pmc">PMC5396475</ArticleId><ArticleId IdType="pubmed">28424376</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SA, Waters NJ. Pharmacokinetic and pharmacodynamic considerations for drugs binding to alpha-1-acid glycoprotein. Pharm Res (2018) 36(2):30. doi:&#xa0;10.1007/s11095-018-2551-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-018-2551-x</ArticleId><ArticleId IdType="pmc">PMC7089466</ArticleId><ArticleId IdType="pubmed">30593605</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry D, Sang A, Yin Y, Zheng YY, Morel L. Murine models of systemic lupus erythematosus. J BioMed Biotechnol (2011) 2011:271694. doi:&#xa0;10.1155/2011/271694</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2011/271694</ArticleId><ArticleId IdType="pmc">PMC3042628</ArticleId><ArticleId IdType="pubmed">21403825</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. . Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 64(8):2677&#x2013;86. doi:&#xa0;10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS, Lee EJ, Yeom J, Oh JS, Hong S, Lee CK, et al. . Urine B-2-glycoprotein 1 as a biomarker for diagnosis of systemic lupus erythematosus. Lupus (2021) 30(8):1306&#x2013;13. doi:&#xa0;10.1177/09612033211014268</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211014268</ArticleId><ArticleId IdType="pubmed">33966541</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. . Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int (2018) 93(4):789&#x2013;96. doi:&#xa0;10.1016/j.kint.2017.11.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz N, Michaelson JS, Putterman C. Lipocalin-2, tweak, and other cytokines as urinary biomarkers for lupus nephritis. Ann N Y Acad Sci (2007) 1109:265&#x2013;74. doi:&#xa0;10.1196/annals.1398.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1398.032</ArticleId><ArticleId IdType="pubmed">17785315</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin BH, Birmingham DJ, Nagaraja HN, Yu CY, Hebert LA. Biomarker discovery in human sle nephritis. Bull NYU Hosp Jt Dis (2007) 65(3):187&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">17922668</ArticleId></ArticleIdList></Reference><Reference><Citation>Urrego-Callejas T, &#xc1;lvarez SS, Arias LF, Reyes BO, Vanegas-Garc&#xed;a AL, Gonz&#xe1;lez LA, et al. . Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis. Clin Rheumatol (2021) 40(5):1853&#x2013;9. doi:&#xa0;10.1007/s10067-020-05454-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05454-0</ArticleId><ArticleId IdType="pubmed">33079302</ArticleId></ArticleIdList></Reference><Reference><Citation>Urrego T, Ortiz-Reyes B, Vanegas-Garcia AL, Munoz CH, Gonzalez LA, Vasquez G, et al. . Utility of urinary transferrin and ceruloplasmin in patients with systemic lupus erythematosus for differentiating patients with lupus nephritis. Reumatol Clin (Engl Ed) (2020) 16(1):17&#x2013;23. doi:&#xa0;10.1016/j.reuma.2018.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2018.02.002</ArticleId><ArticleId IdType="pubmed">29530762</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljaberi N, Bennett M, Brunner HI, Devarajan P. Proteomic profiling of urine: implications for lupus nephritis. Expert Rev Proteomics (2019) 16(4):303&#x2013;13. doi:&#xa0;10.1080/14789450.2019.1592681</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14789450.2019.1592681</ArticleId><ArticleId IdType="pmc">PMC6693508</ArticleId><ArticleId IdType="pubmed">30855196</ArticleId></ArticleIdList></Reference><Reference><Citation>Anjo SI, Santa C, Manadas B. Swath-ms as a tool for biomarker discovery: from basic research to clinical applications. Proteomics (2017) 17(3-4):1600278. doi:&#xa0;10.1002/pmic.201600278</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.201600278</ArticleId><ArticleId IdType="pubmed">28127880</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MX, Zhang Y, Fernie AR, Liu YG, Zhu FY. Swath-ms-bsed poteomics: strategies and applications in plants. Trends Biotechnol (2021) 39(5):433&#x2013;7. doi:&#xa0;10.1016/j.tibtech.2020.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2020.09.002</ArticleId><ArticleId IdType="pubmed">33036785</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M, Wiers K, Brooks EB, Greis KD, Haines K, Klein-Gitelman MS, et al. . Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr Res (2009) 65(5):530&#x2013;6. doi:&#xa0;10.1203/PDR.0b013e31819e4305</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/PDR.0b013e31819e4305</ArticleId><ArticleId IdType="pmc">PMC2737257</ArticleId><ArticleId IdType="pubmed">19218887</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner HI, Bennett MR, Mina R, Suzuki M, Petri M, Kiani AN, et al. . Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum (2012) 64(8):2687&#x2013;97. doi:&#xa0;10.1002/art.34426</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34426</ArticleId><ArticleId IdType="pmc">PMC3381849</ArticleId><ArticleId IdType="pubmed">22328173</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh VK, Fudenberg HH. Lymphocyte stimulation in vitro by orosomucoid glycoprotein. Immunol Lett (1986) 14(1):9&#x2013;13. doi:&#xa0;10.1016/0165-2478(86)90013-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-2478(86)90013-1</ArticleId><ArticleId IdType="pubmed">3492444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng L, Chen N, Liao J, Shen X, Song S, Wang F. Metabolic analysis of potential key genes associated with systemic lupus erythematosus using liquid chromatography-mass spectrometry. Comput Math Methods Med (2021) 2021:5799348. doi:&#xa0;10.1155/2021/5799348</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/5799348</ArticleId><ArticleId IdType="pmc">PMC8505100</ArticleId><ArticleId IdType="pubmed">34646335</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukui H, Taniguchi A, Sakamoto S, Kawahara S, Matsunaga T, Taira K, et al. . Antithrombin iii in children with various renal diseases. Pediatr Nephrol (1989) 3(2):144&#x2013;8. doi:&#xa0;10.1007/BF00852896</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00852896</ArticleId><ArticleId IdType="pubmed">2642093</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. . American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) (2012) 64(6):797&#x2013;808. doi:&#xa0;10.1002/acr.21664</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.21664</ArticleId><ArticleId IdType="pmc">PMC3437757</ArticleId><ArticleId IdType="pubmed">22556106</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. . 2019 Update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (Eular/Era-Edta) recommendations for the management of lupus nephritis. Ann Rheum Dis (2020) 79(6):713&#x2013;23. doi:&#xa0;10.1136/annrheumdis-2020-216924</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F, Wu LH, Tan Y, Li LH, Wang CL, Wang WK, et al. . Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 international society of nephrology and renal pathology society system. Kidney Int (2010) 77(9):820&#x2013;9. doi:&#xa0;10.1038/ki.2010.13</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2010.13</ArticleId><ArticleId IdType="pubmed">20182417</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Healy H, Kassianos AJ. The emerging role of renal tubular epithelial cells in the immunological pathophysiology of lupus nephritis. Front Immunol (2020) 11:578952. doi:&#xa0;10.3389/fimmu.2020.578952</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.578952</ArticleId><ArticleId IdType="pmc">PMC7538705</ArticleId><ArticleId IdType="pubmed">33072122</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Riverol Y, Bai J, Bandla C, Hewapathirana S, Garc&#xed;a-Seisdedos D, Kamatchinathan S, et al. . The PRIDE database resources in 2022: A Hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res (2022) 50(D1): D543&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8728295</ArticleId><ArticleId IdType="pubmed">34723319</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>